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Abstract
Background: High doses and vegetable origin of lipid emulsions (LE) are prominent factors for liver test (LT)
alterations in patients treated with parenteral nutrition (PN). This study aims to determine incidence of LT
alterations, and risk factors related to these alterations in patients with short term PN with homogenous LE.
Methods: Adult non-critically ill hospitalized patients, with normal LTs at the beginning of PN, receiving
0.8 g/kg/day of an olive/soybean LE were included. A paired Student t-test was applied to compare final
with initial LT values. LT variation (end vs start of PN) according to type of surgery and infection was studied by means
of an analysis of the variance. Univariate and multivariate analyses were constructed to relate the variations of each of
the 4 LTs with the adjustment variables.
Results: One hundred eighty one patients (66.57 ± 12.89 years; 72.4% men), 66.8% suffered from cancer. Final LT values
increased from initial values for gamma-glutamyltransferase (GGT) 2.69 ± 2.49 μkat/L vs 0.55 ± 0.36 μkat/L,
alkaline phosphatase (AP) 1.97 ± 1.49 μkat/L vs 1.04 ± 0.33 μkat/L, and alanine aminotransferase (ALT) 0.57 ± 0.
92 μkat/L vs 0.32 ± 0.26 μkat/L. GGT and AP variations were associated with days of PN; GGT, AP and total
bilirubin with surgical patients, AP variations with infection, and GGT with cancer. Multivariate analysis:
elevation of GGT, AP and ALT was related to infection, days of PN and surgery.
Conclusions: Factors that increased the risk of LTs elevation during short term PN treatment were duration
of PN, surgery, cancer, and infection associated with oxidative stress.
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Introduction
Alterations of liver tests (LTs), common in patients with
parenteral nutrition (PN), have a multifactorial component.
There are associated factors, such as the basal clinical state
(liver or biliary disease, abdominal surgery and sepsis) and
pharmacological treatments (hepatotoxic drugs, transfu-
sions), but there are also factors inherent in PN itself and
in lack of oral intake [1–3]. In short-term PN, these
alterations usually revert upon discontinuation of nutri-
tional therapy and are not associated with liver damage.
Clinical manifestations, such as cholestasis or steatosis,
have been described mainly after prolonged periods of PN
especially in premature infants.
An association between the administration of lipid
emulsions (LE) and the alterations of LTs has been de-
scribed. Some studies related this alteration to high doses
of LE [4, 5] and others to the emulsions’ vegetable origin
[6–8]. Our group has studied the impact of vegetal LE on
the alteration of LTs, as well as the protective effect
of fish oil, and our findings support the hypothesis of
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an association between liver damage and use of vegetal LE
[9, 10] due, in part, to plasma phytosterol concentration.
This association is relatively well established in premature
infants and adults with long-term PN, as well as those on
home PN (HPN) [11]. Adult inpatients often receive PN
during the acute phase of their disease, PN thereby coexist-
ing with clinical situations that also alter LTs. The diversity
of clinical situations and the different types of nutrient
used make it difficult to differentiate and establish the
weight and importance of potentially hepatotoxic factors.
The recognition of risk factors associated with LT alter-
ations, as well as early detection of impaired hepatic func-
tion with specific indicators, may allow better nutritional
design for prevention and/or treatment of these alterations.
The objective of this study was to determine in
non-critically ill adult inpatients treated with short
term PN with an olive/soybean LE at a fixed dose of
0.8 g/kg/day, without oral/enteral support:
– The incidence of LT alterations [gamma-glutamyl
transferase (GGT), alkaline phosphatase (AP), alanine
aminotransferase (ALT) and total bilirubin (TB)].
– Demographic and clinical factors, independent of LE
type, related to the LT alterations.
Methods
Population and follow-up time
The study included adult hospitalized patients with normal
LTs at the beginning of PN who received a lipid intake of
0.8 g/kg/day of an olive/soybean LE (Clinoleic®). Patients
without total biochemical and hematological values at
baseline, those with plasma triglycerides ≥3 mmol/L,
pregnant women, nursing mothers, transplanted pa-
tients, patients admitted to critical units, and patients
receiving corticosteroids or immuno-suppressants in
the month prior to the study were excluded.
Patients were studied during the days that they main-
tained a lipid intake of 0.8 g/kg/day with olive oil/soybean
(Clinoleic®) without supplemental oral or enteral nutrition.
Follow-up was discontinued if there was a change of lipid
dose for any reason, including increased triglyceridemia
(≥3mmol/L), and transfer to critical units.
Variables
Demographic and clinical variables were collected: age,
height, weight and diagnosis.
As dependent variables, LTs were studied taking as refer-
ence the following normal values (calculated as the average
of the reference values of our hospital): GGT < 1.11 μkat/L;
AP < 1.5 μkat/L; ALT < 0.73 μkat/L; TB < 17mmol/L.
The following adjustment variables were used:
 Demographic: sex, body mass index (BMI)
 Clinical: diagnostic, infection, surgery and cancer
 Plasmatic safety and follow-up parameters:
creatinine, triglycerides, glucose, albumin, C-
reactive protein (CRP), leukocytes, lymphocytes,
platelet count and prothrombin time
 Nutritional data: days of PN
Statistics
To compare final with initial LT values, a paired Student
t-test was applied.
LT variations (differences between the values at the
start and the end of the study) according to the type of
surgery and infection localization were studied by means
of an analysis of variance (ANOVA).
Univariate analyses were constructed to compare the
variations of each of the four LTs (differences between
the values at the end of the study and the initial values)
with each one of the adjustment variables:
– Linear regression was used for the continuous
variables (days of study, CRP, BMI, triglycerides,
glycemia, leukocytes, lymphocytes, creatinine,
albumin, platelets and prothrombin time)
– Student t-test for binary categorical variables
(sex and cancer)
– ANOVA for each of the three-categorical variables
of infection and surgery classified as not present,
present at the beginning of PN or developed during
PN treatment.
A multivariate approach was developed to study the
relationship between LT variations and the risk factors
studied; a stepwise linear regression model with an in-
clusion criterion of p < 0.1 was used for all variables.
Results
A total of 181 patients with the diagnoses shown in Table 1
were included in the study; 66.8% of patients had neo-
plasms. The most prevalent diagnosis, representing 60.2%
of the cases, was digestive cancer: colonic (18.2%), rectum
(17.1%), gastric (13.3%) and esophagus (6.1%).
Table 1 Diagnostics
Diagnostic n %
Digestive cancer 109 60.2
Non digestive cancer 12 6.6
Fistula 9 5.0
Diverticulitis 9 5.0
Abdominal adhesions 8 4.4
Digestive occlusion 6 3.3
Inflammatory bowel disease 6 3.3
Others 22 12.2
Total 181 100
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Table 2 shows demographic, clinical and nutritional
characteristics together with analytical values at the be-
ginning of PN and at the end of follow-up. Overall,
79.6% of patients were surgical cases and 37% had infec-
tions. Among plasmatic parameters studied, except for
albumin and leukocytes, statistically significant differ-
ences were found between the initial and final values of
the study. Except for GGT and AP, final values of the
analytical variables were within normal range.
Elevation of LT final values was studied, taking into ac-
count 3 scenarios: elevation compared to the initial
values; final values above normal limits; and final values
doubling initial values (Table 3). GGT and AP were the
most frequently elevated LTs. GGT elevations appeared
earlier than AP, which tended to occur more gradually
over the course of PN (Figs. 1 and 2).
Sixty-seven patients had infections confirmed by a
positive culture (37%). Eighty-four infection focuses
Table 2 Demographic, clinical, nutritional and analytical characteristics
Demographics Value
Men (n, %) 131 (72.4)
Age (years±SD) 66.57 ± 12.89
Weight (Kg ± SD) 68.79 ± 13.15
Height (cms ± SD) 166.00 ± 8.85
Clinical data
Cancer (patients: n, %) 121 (66.8)
Infection (patients: n, %) 67 (37.0)
Infection before PN treatment (focus: n, %) 35 (19.3)
Infection during PN treatment (focus: n, %) 50 (27.6)
Type of infection:
Abdominal (patients: n, %) 26 (30.9)
Surgical wound (patients: n, %) 17 (20.2)
Urinary (patients: n, %) 18 (21.4)
Pulmonary (patients: n, %) 9 (10.7)
Bacteriemia (patients: n, %) 14 (16.7)
Surgery (patients: n, %) 144 (79.6)
Surgery before PN treatment (patients: n, %) 139 (76.8)
Surgery during PN treatment (patients: n, %) 12 (6.6)
Nutritional data
Days of follow-up (days ±SD) 8.43 ± 6.64






Gamma-glutamyl transferase (μkat/L) 0.55 ± 0.36 2.69 ± 2.49 0.000
Alkaline phosphatase (μkat/L) 1.04 ± 0,33 1.97 ± 1.49 0.000
Alanine aminotransferase (μkat/L) 0.32 ± 0.26 0.57 ± 0.92 0.000
Total bilirubin (μmol/L) 6.98 ± 4.55 6.08 ± 5.37 0.029
C-reactive protein (mg/L) 139.23 ± 111.99 99.72 ± 108.81 0.000
Albumin (g/L) 28.44 ± 5.50 29.14 ± 5.55 0.061
Leucocytes (x10E9/L) 10.79 ± 5.27 10.45 ± 4.89 0.427
Lymphocytes (x10E9/L) 1.02 ± 0.52 1.31 ± 1.21 0.000
Triglycerides (mmol/L) 1.42 ± 0.66 1.85 ± 0,72 0.000
Glucose (mmol/L) 7.02 ± 2.44 6.44 ± 1.81 0.000
Creatinine (μmol/L) 78.94 ± 53.61 71.27 ± 46.69 0.000
Platelets (x10E9/L) 270.01 ± 108.14 370.98 ± 159.14 0.000
Prothrombin time 1.18 ± 0,15 1.16 ± 0,13 0.014
SD standard deviation
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were detected because 18 patients (9.9%) presented
with more than one infection focus. No statistically
significant differences were found studying LT varia-
tions in relation to the origin of the infection (data
not shown). Meanwhile statistically significant differ-
ences were found in the relationship between differ-
ent types of surgery and the variation of AP, whereas
for GGT there was only a tendency to signification
(Table 4). The major AP and GGT increases were
found for small bowel resection and gastroesopha-
geal surgery, respectively.
Table 5 shows the univariate study of LT variations
and each of the variables studied:
– Among the clinical variables, surgery showed
statistically significant differences in GGT, AP and
TB variations; infection and cancer were
significantly associated with variations of AP with
GGT, respectively.
– CRP was the only plasmatic parameter that showed
statistically significant differences being associated
only with AP variations.
– For nutritional parameters, the number of days of
PN was associated with GGT and AP variations.
– Leukocytes at the end of study were associated with
BIL variations.
– Body Mass Index, Triglycerides, Glycemia,
Lymphocytes, Creatinine, Albumin, Platelets
Prothrombin time and sex did not show statistically
significant differences in any LT.
After obtaining these results we chose a stepwise mul-
tiple linear regression model with an inclusion criterion
of p < 0.1 for all variables in order to achieve maximum
explanatory models.
The results of the multivariate analysis are shown in
Table 6. Variation of AP presents the highest determin-
ation coefficient (R2 0.523) and includes 5 variables.
GGT variation presents a R2 0.150 and includes 4 vari-
ables. The TB and ALT variations have 0.089 and 0.05
R2 values and include 3 and 1 variable, respectively.
Infection, days of PN, and surgery were related to the
elevation of 3 of the LTs studied (GGT, AP and ALT).
The variable days of study had noticeable effect in the
variation of AP. In fact, the mean number of days it took
patients to present AP values above 2-fold their normal
value was 13.94 ± 15.03 with statistically significant dif-
ferences (p < 0.05) in patients who did not present this
elevation (6.81 ± 4.40 days) (Fig. 1). The mean number of
days it took patients to present GGT values above twice








values higher than 2-
fold the initial values
N % n % n %
GGT 175 96.7 131 72.4 85 47.0
AP 170 93.9 107 59.1 19 10.5
ALT 122 67.4 33 18.2 7 3.9
TB 62 34.3 3 1.7 2 1.1
GGT Gamma-glutamyl transferase (μkat/L), AP Alkaline phosphatase (μkat/L),
ALT Alanine aminotransferase (μkat/L), TB Total bilirrubin (μmol/L)
Fig. 1 Days in treatment with parenteral nutrition and alkaline phosphatase values. Mean ± standard deviation of days of parenteral nutrition in
patients that doubled the normal value of alkaline phosphatase vs those that did not: 13.94 ± 15.03 vs 6.81 ± 3.75
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their normal value was 7.89 ± 8.03. No statistical differ-
ences were found with patients who did not present this
elevation (7.03 ± 5.20 days) (Fig. 2). The mean number of
days it took patients to present TB values above their
initial value was 8.92 ± 10.04 with a tendency to signifi-
cance (p < 0.11) compared with those who did not
present this elevation (6.88 ± 3.75 days). Finally, high
values of CRP were only significantly associated with in-
creases in AP, while high values of leukocytes only had a
tendency to be related to TB elevation (Table 6).
Discussion
Our results indicate that clinical situations associated
with oxidative stress, inflammation and days of PN
treatment are independent risk factors in the early onset
of impaired hepatic function. As far as we know, this is
the first time that this complication has been studied in
a group of non-critical patients, homogeneous with re-
gard to PN (same lipid composition same LE adjusted
dose per kg, normal initial LT values), and without oral
or enteral nutrition intake. The selection criteria that we
used in the study attempted to pre-determine the risk fac-
tors more readily associated with the early alteration of
LTs in hospitalized adult patients, by controlling nutri-
tional risk factors. In this context, it is relevant to study
comorbidities in stressed patients, as these involve cata-
bolic and inflammatory states that require supportive and
therapeutic interventions associated with LT alterations,
making it difficult to disaggregate the cause. In addition to
these interventions, the comorbidities themselves, with
which these patients usually present, may also be associ-
ated with LT alterations [12], although their impact is not
so clearly established.
With the aim of minimizing the effect of lipids on liver
function, we studied patients with baseline normal LTs
who received the same lipid content and proportions
(olive/soy) at the same dose (0.8 g/kg/day). However,
since we could not rule out the effect of lipid accumu-
lation, which is different for each patient, we intro-
duced the variable days of study. Despite the short
duration, in the multivariate model, the length of treat-
ment with PN increased significantly with GGT and AP
increases.
At the end of the study, like other authors describe
[1, 4, 5], GGT and AP doubled their normal value in
47 and 10.5% of the patients, respectively. The short
period studied (8.43 ± 6.64 days) would explain the
Fig. 2 Days in treatment with parenteral nutrition and Gamma Glutamyl Transferase values. Mean ± standard deviation of days of parenteral
nutrition in patients that doubled the normal value of gamma glutamyl transferase vs those that did not: 7.89 ± 8.03 vs 7.03 ± 5.2 p > 0.05
Table 4 ANOVA showing the variation of liver parameters GGT
and AP and types of surgery: differences between the end and
beginning of the study
Surgery GGT variations AP variations
n Average ± SD Average ± SD
No surgery 41 1.25 ± 2.02 0.57 ± 1.03
Colorectal 77 2.35 ± 2.58 0.87 ± 0.93
Gastroesophagic 30 2.91 ± 2.67 1.07 ± 0.81
Bilio-hepatic and pancreatic 7 1.35 ± 2.41 0.46 ± 0.29
Small intestine and peritoneal 17 2.41 ± 2.57 2.07 ± 3.80
Others [not digestive system]a 9 1.99 ± 2.18 0.91 ± 0.83
Total 181 2.14 ± 2.45 0.94 ± 1.48
F Snedecor (sig.) 2.04 (0.076) 2.84 (0.017)
GGT Gamma-glutamyl transferase (μkat/L), AP Alkaline phosphatase (μkat/L),
SD standard deviation, ANOVA analysis of variance
aOthers [not digestive system]: radical hysterectomy, cystoprostatectomia,
resection of bladder, lymphadenectomy, prosthesis implant, nephrectomy
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low incidence in the alteration of ALT and TB, as per
our previous studies [10, 13] and other reference pub-
lications [14–17]. Such increases of GGT and AP
emerge as early indicators of hepatic dysfunction [15],
whilst ALT and TB are linked to hepatocellular dam-
age and intrahepatic cholestasis [15–17].
Critical patients and those on prolonged PN treatment
were not included in our study. However, an association
was found between infection and significantly elevated
plasma levels of AP and ALT. In a large series of critical
patients, these findings support a relationship between
sepsis and LT alteration [18]. Also in a series of newborns
Table 5 Univariate analysis showing liver test variations and risk factors: differences between the beginning and end of treatment
LT variations R2 B 95% CI p
Linear regression
Days of follow-up (with PN)
GGT 0.041 0.074 1.045–2.117 0.006
AP 0.372 0.135 0.109–0.161 0.000
ALT 0.001 0.004 −0.015-0.024 0.807
TB 0.018 0.101 −0.010-0.213 0.075
CRP at the end of study
GGT 0.009 0.002 −0.001–0.005 0.217
AP 0.043 0.003 0.001–0.005 0.005
ALT 0.000 0.000 −0.001-0.001 0.847
TB 0.002 0.002 −0.009-0.005 0.581
Leukocytes at the end of study
GGT 0.011 0.053 −0.020-0.126 0.157
AP 0.011 0.611 −0.013-0.075 0.168
ALT 0.006 0.014 −0.013-0.040 0.313
TB 0.026 0.166 0.014–0.318 0.032
Cancer
LT variations No (n = 60)
Mean ± SD




GGT 1.48 ± 1.49 2.48 ± 2.76 0.002
AP 0.77 ± 0.97 1.02 ± 1.68 0.283
ALT 0.38 ± 1.42 0.18 ± 0.41 0.293
TB −0.89 ± 6.69 6.69 ± 4.14 0.815
Infection
LT variations No (n = 114)
Mean ± SD
Beginning PN (n = 17)
Mean ± SD




GGT 1.96 ± 2.67 1.76 ± 1.39 2.69 ± 2.14 0.173
AP 0.76 ± 0.93b 0.71 ± 0.62 1.42 ± 2.36b 0.025
ALT 0.16 ± 0.40 0.31 ± 0.68 0.42 ± 1.52 0.223
TB −1.54 ± 4.18 −0.58 ± 3.15 0.18 ± 7.06 0.184
Surgery
LT variations No (n = 37)
Mean ± SD
Beginning PN (n = 132)
Mean ± SD




GGT 1.01 ± 1.54a,b 2.38 ± 2.56a 3.06 ± 2.60b 0.004
AP 0.48 ± 0.99b 0.94 ± 0.99c 2.34 ± 4.27b,c 0.001
ALT 0.25 ± 0.44b 0.25 ± 1.00 0.22 ± 0.48 0.993
TB −2.26 ± 4.98b −0.95 ± 5.19 1.93 ± 3.06b 0.044
GGT Gamma-glutamyl transferase (μkat/L), AP Alkaline phosphatas (μkat/L) e, ALT Alanine aminotransferase (μkat/L), TB Total bilirubin (μmol/L), SD standard
deviation, CRP C-reactive protein, PN parenteral nutrition. R2 determination coefficient B: constant in the statistical model a: differences between no condition and
condition at the beginning of PN, b: differences between no condition and condition during PN treatment, c: statistically significant differences between the
condition at the beginning of PN and the condition appearing during PN treatment
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treated with PN after abdominal surgery, episodes of
sepsis were associated with a 30% increase in bilirubin
levels [19] indicative of the bacterial and fungal infections’
associated with cholestasis. And it has been reported that
infections are associated with the development of liver fi-
brosis in children who receive early PN irrespective of the
duration of PN, mode of administration, and underlying
disease [1, 20, 21]. Possible mechanisms are the capacity
of bacteria to transform chenodeoxycholic acid in to litho-
colic acid, a more hydrophobic and hepatotoxic biliary
acid [22]; accumulation of toxins in the liver due to sepsis
condition leading to activation of the Kupffer cells and
ultimately to hepatic injury [23] or an inflammatory
response in the liver by endotoxin-activated proin-
flammatory cytokine release that may alter the func-
tion of the biliary canaliculum membrane and reduce
biliary flow.
Overexpression in the liver of proteins related to oxi-
dative regulation and cellular protection against oxida-
tive stress (peroxiredosin-4, serotransferrin, glutathione
S-transferase P and Mn-Superoxide dismutase) suggests
that oxidative damage may be one of the main mecha-
nisms to explain liver tissue damage [24]. In animal
models, Fas-mediated mitochondrial changes and apop-
tosis also point to hepatic injury due to oxidative stress
[25]. In our population, a high percentage of patients
had had surgery (79.6%) and, therefore certain levels of
oxidative stress associated with the surgery itself as well
as with anesthesia [26].
More than half the patients studied (66.9%) had a
diagnosis of cancer. Free radicals are not only implicated
in tumor development [27–29], the redox status of cells
may influence the activation of genes [28, 29]. High
levels of reactive oxygen species, which are associated
with oxidative stress and inflammatory processes, are
seen in hepatic disease [30]. In fact, in the four multi-
variate models studied, cancer was included for GGT
and AP models, and was statistically significant in the
GGT model. These results support the hypothesis of the
influence of neoplastic oxidative stress on LD together
with the effects of therapies and comorbidities associated
with cancer.
In this study, we included the inflammatory parameters
CRP and leukocytes, since high levels of reactive oxygen
species, which are associated with oxidative stress and
inflammatory processes, are seen in hepatic disease [27].
During acute inflammation, a series of chemical and
cellular reactions trigger potent vascular changes
(vasodilatation, increased permeability), resulting in in-
creased exudate. These events are regulated exclusively by
mediators of inflammation related to increases in CRP,
among others. Simultaneously, leukocyte activation, in-
duced by chemotactic factors, occurs by phagocytosis
and/or antigen-antibody complexes. The final step in
phagocytosis occurs mainly through oxygen-dependent
mechanisms that generate ROS.
The first limitation of this study is that, given the
multifactorial component of the alterations studied, it is
difficult to differentiate between the possible causes.
However, the restrictive inclusion criteria make possible
a better disaggregation of early indicators of LT alter-
ations in adult patients. Another study limitation is that
changes in parameters are studied but not their impact
on liver function because in clinical practice no invasive
techniques could be contemplated in this population. A
third methodological limitation is the fact that we have
taken the surrogate variable days of PN as an indirect
indicator of the lipid accumulation effect.
Since the clinical conditions and characteristics of the
PN process (lipid overload and absence of oral/enteral
intake) determine the early alteration of LTs, it is im-
portant to design therapeutic approaches that minimize
long-term risk.
The results obtained here would help to reveal pre-
ventive strategies in the initial stages of PN treatment,
such as the use of LE derived from other types of LE
such as fish oil with an anti-inflammatory, antioxidant
and non-phytosterol component.
Table 6 Multiple lineal regressions: differences between liver parameter variations and risk factors (p < 0.1)
Variable GGT variation AP variation ALT variation Bilirubin total variation
B [95% CI] p B [95% CI] p B [95% CI] p B [95% CI] p
Surgery 1.05 [0.29–1.80] 0.007 0.18 [0.14–0.84] 0.006 2.00 [0.14–0.40] 0.014
Days in study 0.08 [0.03–0.13] 0.003 0.12 [0.18–0.17] 0.000 0.10 [−0.01–0.21] 0.072
Cancer 1.06 [0.27–1.84] 0.009 0.178 [−0.15–0.69] 0.060
Infection 0.44 [−0.01–0.88] 0.056 0.162 [0.04–0.68] 0.027 0.08 [0.01–0.16] 0.036
CRP 0.001 [0.00–0.006] 0.035
Leucocytes 0.15 [−0.12–0.29] 0.064
R2 0.150 0.523 0.050 0.089
CI confidence interval (μkat/L), GGT Gamma-glutamyl transferase (μkat/L), AP Alkaline phosphatase (μkat/L), ALT Alanine aminotransferase; B: constant in the
model R2 determination coefficient Creatinine, glucose and Intensive care unit stay do not feature in this model. Bold type indicates significance
Bold means statistically significant
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Finally, we have seen that LF variables are affected by
surgical, neoplastic and infectious processes. Recently it
has been shown that the administration of phytosterols,
specifically stigmasterol, could act by promoting liver
inflammation by activating hepatic macrophages and
acting as TLR agonists (Toll-like receptors) that induce
cytokines [31] concluding that phytosterols by them-
selves are not associated with liver inflammation but act
in the presence of sepsis [32]; this synergy would be one
of our research direction.
Conclusions
In hospitalized adult patients treated with short-term PN,
with normal initial LTs and receiving the same lipid com-
position at the same dose, there is an elevation of LTs,
which is more marked for GGT and AP. The remaining
biochemical and hematological parameters do not alter or
evolve towards normality.
The risk factors that promote this early elevation of some
LTs are events such as surgery-, cancer- and infection-
associated oxidative stress, as well as inflammatory response
(CRP and leukocytes) and days on PN treatment. Thus,
surgery is associated with elevation of 3 of the LTs. The
duration of PN could probably be linked to the cumulative
effect of the administered lipids.
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